Additional information
| Trade Name | Sprycel |
|---|---|
| Generic Name | Dasatinib |
| Manufacturer | Bristol-Myers Squibb |
| Drug Type | Oncology |
| Indication | Blood cancer / Leukamia |
| Doasage Form | Tablet |
| Packaging | 60 Tablets / Bottle |
SPRYCEL (Dasatinib)- 50mg
SPRYCEL (Dasatinib) belongs to the signal transduction inhibitor category of targeted therapies. It particularly interferes with multiple protein-tyrosine kinases.
SPRYCEL is used for;
- Treatment of chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.
- Treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.
